291 related articles for article (PubMed ID: 12240787)
1. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series.
Bullock R; Cameron A
Curr Med Res Opin; 2002; 18(5):258-64. PubMed ID: 12240787
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia.
Rösler M
Int J Clin Pract Suppl; 2002 Jun; (127):20-36. PubMed ID: 12139365
[TBL] [Abstract][Full Text] [Related]
3. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease.
Burn D; Emre M; McKeith I; De Deyn PP; Aarsland D; Hsu C; Lane R
Mov Disord; 2006 Nov; 21(11):1899-907. PubMed ID: 16960863
[TBL] [Abstract][Full Text] [Related]
4. Rivastigmine: in Parkinson's disease dementia.
Siddiqui MA; Wagstaff AJ
CNS Drugs; 2006; 20(9):739-47; discussion 748-50. PubMed ID: 16953649
[TBL] [Abstract][Full Text] [Related]
5. The effects of rivastigmine on neuropsychiatric symptoms in the early stages of Parkinson's disease: A systematic review.
Reilly S; Dhaliwal S; Arshad U; Macerollo A; Husain N; Costa AD
Eur J Neurol; 2024 Feb; 31(2):e16142. PubMed ID: 37975761
[TBL] [Abstract][Full Text] [Related]
6. The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis.
Bullock R
Int J Clin Pract; 2002 Apr; 56(3):206-14. PubMed ID: 12018828
[TBL] [Abstract][Full Text] [Related]
7. Rivastigmine tartrate with a focus on dementia associated with Parkinson's disease.
Wesnes K
Drugs Today (Barc); 2007 Jun; 43(6):349-59. PubMed ID: 17612707
[TBL] [Abstract][Full Text] [Related]
8. Rivastigmine for dementia associated with Parkinson's disease.
Emre M; Aarsland D; Albanese A; Byrne EJ; Deuschl G; De Deyn PP; Durif F; Kulisevsky J; van Laar T; Lees A; Poewe W; Robillard A; Rosa MM; Wolters E; Quarg P; Tekin S; Lane R
N Engl J Med; 2004 Dec; 351(24):2509-18. PubMed ID: 15590953
[TBL] [Abstract][Full Text] [Related]
9. Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia.
Kandiah N; Pai MC; Senanarong V; Looi I; Ampil E; Park KW; Karanam AK; Christopher S
Clin Interv Aging; 2017; 12():697-707. PubMed ID: 28458525
[TBL] [Abstract][Full Text] [Related]
10. Cholinesterase inhibitors for Parkinson's disease dementia.
Maidment I; Fox C; Boustani M
Cochrane Database Syst Rev; 2006 Jan; (1):CD004747. PubMed ID: 16437494
[TBL] [Abstract][Full Text] [Related]
11. Rivastigmine for minor visual hallucinations in Parkinson's disease: A randomized controlled trial with 24 months follow-up.
van Mierlo TJM; Foncke EMJ; Post B; Schmand BA; Bloem BR; van Harten B; Tissingh G; Munts AG; de Haan RJ; de Bie RMA;
Brain Behav; 2021 Aug; 11(8):e2257. PubMed ID: 34291590
[TBL] [Abstract][Full Text] [Related]
12. Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine.
Robert P
Curr Med Res Opin; 2002; 18(3):156-71. PubMed ID: 12094826
[TBL] [Abstract][Full Text] [Related]
13. Rivastigmine (Exelon) for dementia in patients with Parkinson's disease.
Giladi N; Shabtai H; Gurevich T; Benbunan B; Anca M; Korczyn AD
Acta Neurol Scand; 2003 Nov; 108(5):368-73. PubMed ID: 14616309
[TBL] [Abstract][Full Text] [Related]
14. Rivastigmine in vascular dementia.
Moretti R; Torre P; Antonello RM; Cazzato G; Bava A
Expert Opin Pharmacother; 2004 Jun; 5(6):1399-410. PubMed ID: 15163283
[TBL] [Abstract][Full Text] [Related]
15. Rivastigmine and Parkinson dementia complex.
Moretti R; Torre P; Vilotti C; Antonello RM; Pizzolato G
Expert Opin Pharmacother; 2007 Apr; 8(6):817-29. PubMed ID: 17425477
[TBL] [Abstract][Full Text] [Related]
16. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.
Inglis F
Int J Clin Pract Suppl; 2002 Jun; (127):45-63. PubMed ID: 12139367
[TBL] [Abstract][Full Text] [Related]
17. Cholinesterase inhibitors for dementia with Lewy bodies.
Wild R; Pettit T; Burns A
Cochrane Database Syst Rev; 2003; 2003(3):CD003672. PubMed ID: 12917981
[TBL] [Abstract][Full Text] [Related]
18. Parkinson's disease-related visual hallucinations unresponsive to atypical antipsychotics treated with cholinesterase inhibitors: a case series.
Sobow T
Neurol Neurochir Pol; 2007; 41(3):276-9. PubMed ID: 17629823
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study.
McKeith I; Del Ser T; Spano P; Emre M; Wesnes K; Anand R; Cicin-Sain A; Ferrara R; Spiegel R
Lancet; 2000 Dec; 356(9247):2031-6. PubMed ID: 11145488
[TBL] [Abstract][Full Text] [Related]
20. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study.
Poewe W; Wolters E; Emre M; Onofrj M; Hsu C; Tekin S; Lane R;
Mov Disord; 2006 Apr; 21(4):456-61. PubMed ID: 16229010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]